1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator is a flagship funding program under the European Innovation Council (EIC), aimed at supporting small and medium-sized enterprises (SMEs) and startups with breakthrough innovations. It acts as a catalyst for high-risk, high-potential projects that can significantly impact markets and society. The program is particularly focused on fostering innovations in the deep tech sector, which includes advanced technologies such as artificial intelligence, biotechnology, quantum computing, and more.

Grant and Equity Funding

The EIC Accelerator provides blended finance, which includes both grant and equity components:

Purpose in the European DeepTech and Startup Ecosystem

The EIC Accelerator plays a pivotal role in the European deep tech and startup ecosystem by:

• Fostering Innovation: Supporting cutting-edge technologies that have the potential to create new markets or disrupt existing ones.
• Reducing Risk: Offering financial support for high-risk projects that might struggle to secure traditional funding.
• Encouraging Growth: Helping startups scale their operations and access international markets.
• Promoting Sustainability: Prioritizing projects that align with the EU's sustainability goals.

Role in Scaling and Private Sector Funding

The EIC Accelerator helps companies achieve scale by:

• Providing Capital: Offering substantial financial resources to address the funding gap in the commercialization phase.
• Attracting Private Investors: Demonstrating EU endorsement and reducing perceived risk, making companies more attractive to private investors.
• Offering Strategic Support: Through networking opportunities, mentorship, and business acceleration services, the program enhances the strategic capabilities of startups.

GENERA ISTRAZIVANJA and Project OSTEOforUNION

Company Overview: GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODA, based in Croatia, is an innovative biotechnology company focusing on developing advanced biotechnological solutions.

Project OSTEOforUNION: This project addresses the critical medical need for treating bone fracture nonunions. Nonunions occur when a fractured bone fails to heal naturally, leading to chronic pain and disability. OSTEOforUNION aims to develop a novel drug solution that accelerates bone healing, reducing recovery time and improving patient outcomes.

Technology Basics and Background:

• Biotechnological Approach: Utilizing cutting-edge biotechnology to enhance bone regeneration processes.
• Targeted Drug Development: Focusing on specific pathways and biological processes that are crucial for bone repair and regeneration.
• Clinical Impact: Offering a potential breakthrough in orthopedic treatment, providing a less invasive and more effective alternative to current surgical interventions.

By securing EIC Accelerator support, GENERA ISTRAZIVANJA can advance its research, scale its operations, and bring this innovative solution to market, addressing a significant unmet medical need and improving the quality of life for patients with bone fracture nonunions.

2 The Funding Rounds

As of April 15, 2025, there is no publicly available information indicating that GENERA ISTRAZIVANJA d.o.o., a Croatian company specializing in research and development services, has secured any additional funding since receiving EIC Accelerator Blended Finance on March 13, 2024.

According to PitchBook, the company's latest deal type is categorized as "Corporate," with only one financing round recorded. (pitchbook.com) Additionally, Genera d.d., the parent company, was acquired by Dechra Pharmaceuticals on October 21, 2015. (pitchbook.com)

Despite thorough searches across financial databases and company profiles, no further funding rounds, investor information, or company valuations for GENERA ISTRAZIVANJA d.o.o. have been identified beyond the EIC Accelerator funding received in March 2024.

3 The Press Releases

Genera Istraživanja d.o.o., a Croatian biotechnology company, has been actively advancing in the field of regenerative medicine. Since receiving the EIC Accelerator funding on March 13, 2024, the company has made several significant announcements:

1. Clinical Study Milestone: In November 2023, Genera Research announced the successful recruitment of the first patient in Phase II of a clinical study. This study focuses on testing the efficacy, safety, and tolerability of Osteogrow, a recombinant human bone morphogenetic protein 6 in autologous blood coagulum, for alveolar ridge regeneration following tooth extraction. The clinical site for this groundbreaking study is the prestigious Stomatology Faculty of the University of Zagreb. (genera-research.com)

2. Recognition in European Commission's CORDIS: In November 2023, the OSTEOproSPINE project, with Genera Research as a clinical trials sponsor and consortium partner, was spotlighted by CORDIS in the ‘Results in Brief’ section of the European Commission’s website. This recognition underscores the significant strides in developing Osteogrow, a novel treatment promising to revolutionize bone regeneration and alleviate chronic lumbar back pain in the EU. The Phase II clinical trial has shown that Osteogrow can effectively stabilize the lumbar spine and mitigate pain recurrence. The anticipated introduction of Osteogrow-C in the EU market by 2028 is set to substantially impact patients' quality of life. (genera-research.com)

3. Symposium Participation: In November 2023, Genera Research participated as a partner in the Symposium on Regenerative Medicine - New Platforms and Potentials, hosted by the Center of Excellence for Reproductive and Regenerative Medicine (CERRM) – Subunit for Regenerative Medicine. The event took place at the Amadria Park Hotel Royal in Opatija from October 23-25, 2023, featuring guest lecturers from Genera Research's esteemed team. (genera-research.com)

4. Academic Engagement: In October 2022, Genera Research's Chief Operating Officer, Dora Adanić, served as a guest lecturer at Libertas International University in Zagreb. She delivered a lecture on "Development and clinical testing of Osteogrow, the first Croatian drug for global use," under the guidance of doc. Dr.sc. Helena Šlogar. (genera-research.com)

These developments highlight Genera Istraživanja's commitment to advancing regenerative medicine and its active engagement in both clinical research and academic collaboration.

4 The Technology Advancements

Genera Istraživanja d.o.o., a Croatian company specializing in the production of biotechnological products, was awarded EIC Accelerator funding on March 13, 2024, for their project "OSTEOforUNION," aimed at developing a drug solution for bone fracture nonunions. (strata.team)

Technology Advancements Since EIC Accelerator Funding:

As of April 16, 2025, there is limited publicly available information detailing the specific technological advancements Genera Istraživanja has achieved since receiving the EIC Accelerator funding. The company's official website and recent press releases do not provide updates on the progress of the "OSTEOforUNION" project or other technological developments.

Scaling of Technology:

Due to the lack of detailed public information, it is unclear whether Genera Istraživanja has been able to scale their technology or if it remains in the development phase. The absence of updates suggests that the project may still be in the early stages of development.

Market Demonstration:

There is no available evidence indicating that Genera Istraživanja has demonstrated their technology in the market, either through customer engagements or demonstrator projects. The company's public communications do not mention any partnerships, clinical trials, or market introductions related to "OSTEOforUNION."

Intellectual Property and Publications:

Information regarding new patents, scientific studies, clinical trials, or whitepapers filed by Genera Istraživanja since receiving the EIC Accelerator funding is not publicly accessible. The company's official channels do not disclose any recent intellectual property activities or publications.

In summary, while Genera Istraživanja has secured EIC Accelerator funding for their "OSTEOforUNION" project, there is a lack of publicly available information detailing their technological advancements, scaling efforts, market demonstrations, or intellectual property activities since the funding was awarded.

5 The Partnerships and Customers

As of April 16, 2025, there is no publicly available information detailing specific partnerships or customers that Genera Istraživanja Društvo S Ograničenom Odgovornošću Za Proizvodnju Biotehnoloških Proizvoda has established since receiving EIC Accelerator funding on March 13, 2024. The company is developing OSTEOforUNION, a drug solution for bone fracture nonunions. (strata.team)

The EIC Accelerator funding is designed to support companies in scaling up high-impact innovations with the potential to create or disrupt markets. (eic.ec.europa.eu) For Genera Istraživanja, this funding likely aims to advance the development and commercialization of OSTEOforUNION, positioning the company to address unmet medical needs in bone fracture healing.

While specific details about new partnerships or customers are not available, the EIC Accelerator's support typically includes access to a range of Business Acceleration Services. These services provide connections to global partners, coaching, mentoring, and networking opportunities, which can facilitate strategic collaborations and market expansion. (eic.ec.europa.eu)

By leveraging these resources, Genera Istraživanja can enhance its market position and accelerate the scaling of its innovative biotechnological product.

6 The Hiring and Company Growth

As of April 15, 2025, there is limited publicly available information regarding the hiring activities or team growth of Genera Istraživanja d.o.o. since receiving EIC Accelerator funding on March 13, 2024. Specific details about their current headcount, team size, recent hires, or management changes are not readily accessible through public sources.

However, it's noteworthy that the biotechnology sector has been experiencing significant growth and transformation globally. For instance, the AI market in recruitment is projected to grow by USD 290.07 million from 2024 to 2028, with a compound annual growth rate (CAGR) of 7.87%. This growth is driven by the increasing need for automated processes in the recruitment industry, which could influence hiring practices in biotech companies. (prnewswire.com)

Additionally, the integration of generative AI (GenAI) into various sectors has been notable. The share of job postings mentioning GenAI or related terms has increased significantly over the past year, indicating a broader trend towards adopting advanced technologies in the workplace. (hiringlab.org)

While specific information about Genera Istraživanja's hiring activities post-EIC funding is not publicly available, these industry trends suggest a dynamic environment that may influence their growth and recruitment strategies.

7 The Media Features and Publications

As of April 15, 2025, there is limited publicly available information regarding media features, publications, podcasts, interviews, conferences, fairs, presentations, or events involving GENERA ISTRAŽIVANJA DRUŠTVO S OGRANIČENOM ODGOVORNOŠĆU ZA PROIZVODNJU BIOTEHNOLOŠKIH PROIZVODA since they received EIC Accelerator funding on March 13, 2024. The company's project, OSTEOforUNION, focuses on developing a drug solution for bone fracture nonunions. (strata.team)

While specific details about the company's activities post-funding are scarce, their official website provides insights into their ongoing research and development efforts. Genera Research Ltd. is a clinical-stage biotechnology company based in Croatia, specializing in recombinant human Bone Morphogenetic Protein (BMP) products for tissue regeneration and orthopedic procedures. Their portfolio includes over 30 globally protected patents, and they are conducting clinical trials for their patented innovation, "OSTEOGROW," a family of biological products aimed at bone healing. (genera-research.com)

For the most current information on their media appearances, publications, and event participations since March 13, 2024, it is advisable to monitor their official website and reputable news outlets for updates.